Literature DB >> 18800152

Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates.

F Sakurai1, S-i Nakamura, K Akitomo, H Shibata, K Terao, K Kawabata, T Hayakawa, H Mizuguchi.   

Abstract

Adenovirus (Ad) serotype 35 (Ad35) vectors have attracted remarkable attention as alternatives to conventional Ad serotype 5 (Ad5) vectors. In a previous study, we showed that intravenously administered Ad35 vectors exhibited a safer profile than Ad5 vectors in cynomolgus monkeys, which ubiquitously express CD46, an Ad35 receptor, in a pattern similar to that in humans. However, the Ad35 vectors poorly transduced the organs. In this study, we examined the transduction properties of Ad35 vectors after local administration into organs of cynomolgus monkeys. The vectors transduced different types of cells depending on the organ. Hepatocytes and microglia were mainly transduced after the vectors were injected into the liver and cerebrum, respectively. Injection of the vectors into the femoral muscle resulted in the transduction of cells that appeared to be fibroblasts and/or macrophages. Conjunctival epithelial cells showed transgene expression following infusion into the vitreous body of the eyeball. Transgene expression was limited to areas around the injection points in most of the organs. In contrast, Ad35 vector-mediated transgene expression was not detected in any of the organs not injected with Ad35 vectors. These results suggest that Ad35 vectors are suitable for gene delivery by direct administration to organs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800152     DOI: 10.1038/gt.2008.154

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  3 in total

1.  Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35.

Authors:  Stefan Kälin; Beat Amstutz; Michele Gastaldelli; Nina Wolfrum; Karin Boucke; Menzo Havenga; Fabienne DiGennaro; Nicole Liska; Silvio Hemmi; Urs F Greber
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

Review 2.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

Review 3.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.